The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•31 March 2026•

1 min read

Novo Nordisk Slashes Ozempic and Wegovy Prices in India to Combat Generic Competition

Key Facts

1Novo Nordisk slashed Ozempic prices by 36% and Wegovy by 48% in India.

2The decision aims to counter rising competition from local drugmakers launching cheaper generic alternatives.

Version History

1 additional source confirmed this story

Danish pharmaceutical giant Novo Nordisk has announced significant price reductions for its flagship diabetes and weight-loss drugs in the Indian market. The company slashed the price of Ozempic by 36% and Wegovy by 48% as it faces an influx of low-cost generic alternatives from local manufacturers. This strategic move aims to defend Novo Nordisk's market share in one of the world's fastest-growing healthcare markets. Analysts note that while the price cuts will help maintain sales volume, they signal increasing margin pressure on the company's blockbuster semaglutide products. The entry of cheaper generic versions has effectively ended the firm's exclusive pricing power in the region. Investors are closely monitoring how these adjustments will impact the company's long-term profitability in emerging markets.